Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study uses CT scans to track liver changes after radiation

NCT ID NCT07320755

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will use CT scans to measure how the liver changes in size after radiation therapy. Researchers will look at scans taken before and after treatment in 70 adults with cancers near the liver. The goal is to better understand liver response to radiation and improve future treatment planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better plan radiotherapy to protect the liver and reduce the risk of liver damage.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in patient care, and results may vary among individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients who have received radiotherapy for liver or nearby tumors and have available pre-treatment and post-treatment CT imaging for assessment of liver volume changes. Both males and females are included, with a minimum age of 18 years and no upper age limit. Participants are selected based on availability of imaging data from routine clinical care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Inclusion criteria: * Adults aged 18 years or older. * Received radiation therapy (RT) involving the liver (e.g., SBRT, IMRT). The study involves patients in whom the liver was exposed to radiotherapy, either as a direct target (in hepatic-directed treatments as in HCC or liver metastasis) or indirectly as an organ-at-risk (OAR) during irradiation of nearby anatomical regions (as lower lung, gastric, or abdominal sites) where the liver was partially included within the radiation field. The analysis aims to evaluate radiation-induced volumetric changes regardless of whether the liver was the primary target or secondarily affected. * Availability of paired pre- and post-RT CT scans of sufficient quality. * 3D dose distribution data from the RT treatment plan. * Clinical follow-up data, including liver function tests and toxicity records. * No evidence of major anatomical changes between scans unrelated to RT (e.g., surgery). 2. Exclusion criteria: * Patients with a history of major liver surgery (e.g., resection or transplant) between the pre- and post-RT scans. * Presence of severe motion artifacts or poor-quality CT scans that hinder accurate image analysis. * Incomplete or missing 3D radiation dose distribution data. * Lack of sufficient clinical follow-up information (e.g., liver function tests, toxicity outcomes). * Concurrent systemic therapies (e.g., chemotherapy or immunotherapy) during the imaging interval that may confound liver volume changes, unless controlled for in analysis. * Pre-existing liver conditions that could independently alter liver volume (e.g., cirrhosis, advanced hepatic steatosis) if not accounted for. * Patients under 18 years of age.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intra-abdominal malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.